Analysts Issue Forecasts for Belite Bio FY2025 Earnings

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Belite Bio in a report released on Monday, December 1st. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($2.15) per share for the year, down from their prior estimate of ($1.97). HC Wainwright has a “Buy” rating and a $185.00 price objective on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q4 2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at $5.80 EPS and FY2026 earnings at $4.12 EPS.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, December 1st. The company reported $0.95 earnings per share (EPS) for the quarter.

Several other analysts have also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a report on Wednesday, October 8th. BTIG Research set a $187.00 price objective on shares of Belite Bio in a report on Wednesday. Mizuho set a $194.00 price objective on shares of Belite Bio and gave the company an “outperform” rating in a research report on Tuesday. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research note on Wednesday. Finally, Cantor Fitzgerald initiated coverage on shares of Belite Bio in a research note on Monday, November 24th. They set an “overweight” rating and a $154.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Belite Bio Stock Performance

Shares of BLTE opened at $151.27 on Wednesday. The stock has a fifty day moving average price of $103.50 and a two-hundred day moving average price of $77.80. Belite Bio has a 52-week low of $49.00 and a 52-week high of $160.55. The company has a market cap of $5.28 billion, a price-to-earnings ratio of -78.79 and a beta of -1.45.

Institutional Trading of Belite Bio

A number of institutional investors have recently bought and sold shares of BLTE. Alyeska Investment Group L.P. bought a new stake in shares of Belite Bio during the 1st quarter valued at $5,538,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Belite Bio during the second quarter worth $147,000. Marshall Wace LLP acquired a new stake in shares of Belite Bio during the second quarter worth $547,000. BNP Paribas Financial Markets bought a new stake in Belite Bio in the second quarter valued at about $190,000. Finally, GAMMA Investing LLC lifted its stake in Belite Bio by 11.1% in the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock valued at $130,000 after buying an additional 176 shares during the period. Institutional investors and hedge funds own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.